Neuberger Berman Group LLC Grows Stake in Kenvue Inc. $KVUE

Neuberger Berman Group LLC boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 19.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,026,137 shares of the company’s stock after acquiring an additional 336,982 shares during the quarter. Neuberger Berman Group LLC owned 0.11% of Kenvue worth $32,884,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Aptus Capital Advisors LLC increased its position in shares of Kenvue by 8.9% during the 3rd quarter. Aptus Capital Advisors LLC now owns 15,081 shares of the company’s stock valued at $245,000 after purchasing an additional 1,230 shares during the last quarter. Longfellow Investment Management Co. LLC grew its position in Kenvue by 32,077.5% during the third quarter. Longfellow Investment Management Co. LLC now owns 25,742 shares of the company’s stock valued at $418,000 after buying an additional 25,662 shares during the period. Skba Capital Management LLC grew its position in Kenvue by 24.0% during the third quarter. Skba Capital Management LLC now owns 845,775 shares of the company’s stock valued at $13,727,000 after buying an additional 163,900 shares during the period. Dimensional Fund Advisors LP increased its holdings in Kenvue by 13.5% during the third quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock valued at $375,377,000 after buying an additional 2,747,952 shares during the last quarter. Finally, South Dakota Investment Council increased its holdings in Kenvue by 4.5% during the third quarter. South Dakota Investment Council now owns 229,703 shares of the company’s stock valued at $3,728,000 after buying an additional 9,890 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 0.9%

Shares of KVUE stock opened at $18.41 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The company’s fifty day moving average price is $17.85 and its 200-day moving average price is $17.43. The company has a market capitalization of $35.29 billion, a price-to-earnings ratio of 23.91, a PEG ratio of 4.21 and a beta of 0.51.

Kenvue (NYSE:KVUE) last issued its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The company had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. During the same quarter in the prior year, the firm posted $0.26 EPS. Kenvue’s quarterly revenue was up 3.2% compared to the same quarter last year. Sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.5%. Kenvue’s dividend payout ratio is 107.79%.

Insider Activity

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the purchase, the director owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. This trade represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.68% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on KVUE. Canaccord Genuity Group lifted their price target on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Barclays upped their price objective on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Friday. Citigroup raised their target price on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. UBS Group lifted their target price on Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. Finally, Zacks Research raised Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Three investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $19.58.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.